Peltomaki K P, Lothe R A, Aaltonen L A, et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome [J]. Cancer Res, 1993, 53(24): 5853-5855.
Mcconechy M K, Talhouk A, Li-Chang H H, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas [J]. Gynecol Oncol, 2015, 137(2): 306-310.
[6]
Corso G, Velho S, Paredes J, et al. Oncogenic mutations in gastric cancer with microsatellite instability[J]. Eur J Cancer, 2011, 47(3): 443-451.
[7]
Janavicius R, Matiukaite D, Jakubauskas A, et al. Microsatellite instability detection by high-resolution melting analysis [J]. Clin Chem, 2010, 56(11): 1750-1757.
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[10]
Boland C R, Goel A. Microsatellite Instability in Colorectal Cancer [J]. Gastroenterology, 2010, 138(6): 2073-2087.
[11]
Li X X, Workstation P, University S M, et al. Histopathologic features and microsatellite instability of sporadic colorectal carcinoma: an analysis of 400 cases [J]. World Chin J Digestol, 2013, 21(12): 1080-1089.
Boland C R, Shin S K, Goel A. Promoter methylation in the genesis of gastrointestinal cancer [J]. Yonsei Med J, 2009, 50(3):309-321.
[16]
Chiappini F, Gross-Goupil M, Saffroy R, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers[J]. Carcinogenesis, 2004, 25(4):5 41-547.
[17]
Piao Z, Kim H, Malkhosyan S, et al. Frequent chromosomal instability but no microsatellite instability in hepatocellular carcinomas [J]. Int J Oncol, 2000, 17(3): 507-512.
[18]
Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[19]
Witkowski E R, Smith J K, Tseng J F. Outcomes following resection of pancreatic cancer [J]. J Surg Oncol, 2013, 107(1): 97-103.
Soares K C, Rucki A A, Wu A A, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors [J]. J Immunother, 2015, 38(1): 1-11.
[22]
Kouso H, Yoshino I, Miura N, et al. Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance [J]. J Surg Oncol, 2008, 98(5): 377-383.
[23]
Vageli D, Daniil Z, Dahabreh J, et al. Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas [J]. Lung Cancer, 2009, 64(3): 282-288.
[24]
Quigley D A, Kristensen V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells [J]. Mol Oncol, 2015, 9(10): 2054-2062.
Norris A M, Woodruff R D, D’Agostino R J, et al. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer[J]. Prostate, 2007, 67(2): 214-225.
Pritchard C C, Morrissey C, Kumar A, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer [J]. Nat Commun, 2014, 5(10): 4988-4994.
[29]
Rosty C, Walsh M D, Lindor N M, et al. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry [J]. Fam Cancer, 2014, 13(4): 573-582.
[30]
Dominguez-Valentin M, Joost P, Therkildsen C, et al. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome [J]. BMC Urol, 2016, 16(1): 1-7.
[31]
Chen Y, Wang J, Fraig M M, et al. Defects of DNA mismatch repair in human prostate cancer [J]. Cancer Res, 2001, 61(10): 4112-4121.
[32]
Chuang S T, Adley B, Han M, et al. Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer [J]. Histopathology, 2008, 52(2): 247-250.
[33]
Wong Y F, Cheung T H, Poon K Y, et al. The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix [J]. Gynecol Oncol, 2003, 89(3): 434-439.
Nijhuis E R, Nijman H W, Oien K A, et al. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer [J]. J Clin Pathol, 2007, 60(7): 824-830.
2017, Vol. 28 
